Gikalov I[Author] - Search Results

Year	Number of Results
1972	2
1973	1
1974	1
1976	2
1977	1
1980	1
1982	1
1983	1
1985	2
1986	1
1987	2
1993	2
2023	0

1

Dose-related increase of HDL-cholesterol levels after N-acetylcysteine in man.

Franceschini G, Werba JP, Safa O, Gikalov I, Sirtori CR. Franceschini G, et al. Among authors: gikalov i. Pharmacol Res. 1993 Oct-Nov;28(3):213-8. doi: 10.1006/phrs.1993.1124. Pharmacol Res. 1993. PMID: 8108311

2

Concentration of azapropazone in synovial tissues and fluid.

Spahn H, Thabe K, Mutschler E, Tillmann K, Gikalov I. Spahn H, et al. Among authors: gikalov i. Eur J Clin Pharmacol. 1987;32(3):303-7. doi: 10.1007/BF00607579. Eur J Clin Pharmacol. 1987. PMID: 3595703

3

The frequency of adverse drug reactions as dependent upon age, sex and duration of hospitalization.

Klein U, Klein M, Sturm H, Rothenbühler M, Huber R, Stucki P, Gikalov I, Keller M, Hoigné R. Klein U, et al. Among authors: gikalov i. Int J Clin Pharmacol Biopharm. 1976 Apr;13(3):187-95. Int J Clin Pharmacol Biopharm. 1976. PMID: 950261

4

[Human pharmacokinetics of different i.v. doses of azapropazone (HPLC-determination) (author's transl)].

Gikalov I, Kaufmann R, Schuster O. Gikalov I, et al. Arzneimittelforschung. 1982;32(4):423-6. Arzneimittelforschung. 1982. PMID: 7201814 German.

5

Aminopyrine demethylation measured by breath analysis in cirrhosis.

Bircher J, Küpfer A, Gikalov I, Preisig R. Bircher J, et al. Among authors: gikalov i. Clin Pharmacol Ther. 1976 Oct;20(4):484-92. doi: 10.1002/cpt1976204484. Clin Pharmacol Ther. 1976. PMID: 975720

6

[The clinical pharmacokinetics of allopurinol. 1. Allopurinol absorption sites and dose proportionality of allopurinol/oxipurinol bioavailability].

Schuster O, Haertel M, Hugemann B, Gikalov I, Schiemann O, Fenner H. Schuster O, et al. Among authors: gikalov i. Arzneimittelforschung. 1985;35(4):760-5. Arzneimittelforschung. 1985. PMID: 4015743 German.

7

[Clinical pharmacokinetics of allopurinol. 3. Allopurinol/oxipurinol pharmacokinetics following administration of a controlled release allopurinol preparation].

Gikalov I, Radivojevich F, Schiemann O, Fenner H. Gikalov I, et al. Arzneimittelforschung. 1986 Jun;36(6):988-93. Arzneimittelforschung. 1986. PMID: 3741536 German.

8

[Incidence of adverse effects of drug therapy as a function of age, sex and length of hospitalization].

Klein U, Klein M, Sturm H, Rothenbühler M, Huber R, Stucki P, Gikalov I, Keller M, Hoigné. Klein U, et al. Among authors: gikalov i. Schweiz Med Wochenschr. 1974 Dec 14;104(50):1892-3. Schweiz Med Wochenschr. 1974. PMID: 4445867 German. No abstract available.

9

[The clinical pharmacokinetics of allopurinol. 2. Allopurinol/oxypurinol pharmacokinetics following allopurinol in single doses and multiple application].

Fenner H, Schiemann O, Gikalov I. Fenner H, et al. Among authors: gikalov i. Arzneimittelforschung. 1985;35(7):1093-6. Arzneimittelforschung. 1985. PMID: 4052144 German.

10

[Comparative studies on the bioavailability of 2 amoxicillin preparations].

Gikalov I, Daschner F. Gikalov I, et al. Arzneimittelforschung. 1983;33(5):784-6. Arzneimittelforschung. 1983. PMID: 6683559 German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

17 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year